@TumorBoardTues 1/18 #TumorBoardTuesday #RenalCancer #OncTwitter @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD
65yo👨🏼
hx of R radical Nx
pT3aNx, ISUP G4, ccRCC with rhabdoid diff
🗓️6 mos later
🩻mets to 🫁
👨🏼Asymptomatic
💉1L ipi/nivo then maintenance nivo
🗓️7 mos post Tx initiation
🩻PD in 🫁
65yo👨🏼
hx of R radical Nx
pT3aNx, ISUP G4, ccRCC with rhabdoid diff
🗓️6 mos later
🩻mets to 🫁
👨🏼Asymptomatic
💉1L ipi/nivo then maintenance nivo
🗓️7 mos post Tx initiation
🩻PD in 🫁
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD 2/18 #TumorBoardTuesday @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD #RenalCell
#RCC
👨🏼Tolerates ipi/nivo well except 😴
👨🏼Concerned about worsening fatigue and wondering how to proceed without making it worse.
🤔How do you treat mRCC that has progressed on 1L ipi/nivo?
#RCC
👨🏼Tolerates ipi/nivo well except 😴
👨🏼Concerned about worsening fatigue and wondering how to proceed without making it worse.
🤔How do you treat mRCC that has progressed on 1L ipi/nivo?
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @LuisMezaco
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @LuisMezaco 3/18 #TumorBoardTuesday #ASCO23
👨🏻🏫Mini tweetorial 1 👩🏻🏫
✨CONTACT-03✨
Population:
🔹~30% of patients had ipi/nivo & 50% had IO in 1L
🔹62% had IMDC intermediate risk dz
🔹35% VEGF TKI-naive
📚@montypal @DrChoueiri
(content adapted from @brian_rini @katy_beckermann)
👨🏻🏫Mini tweetorial 1 👩🏻🏫
✨CONTACT-03✨
Population:
🔹~30% of patients had ipi/nivo & 50% had IO in 1L
🔹62% had IMDC intermediate risk dz
🔹35% VEGF TKI-naive
📚@montypal @DrChoueiri
(content adapted from @brian_rini @katy_beckermann)
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @nataliagandur @MosheOrnsteinMD @PGrivasMDPhD @vinay_onc
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @nataliagandur @MosheOrnsteinMD @PGrivasMDPhD @vinay_onc 4/18 #TumorBoardTuesday
👨🏻🏫Mini tweetorial 2 👩🏻🏫
✨CONTACT-03✨
📌Cabozantinib/Atezolizumab vs cabozantinib
❌No improvement mPFS (co-1° endpoint): 10.6 vs 10.8 mos
❌No diff OS (co-1° endpoint): HR 0.94 (95% CI: 0.70-1.27)
❌No diff ORR: 41% both arms
📈Med DOR: 12.7 vs 14.8 mos
👨🏻🏫Mini tweetorial 2 👩🏻🏫
✨CONTACT-03✨
📌Cabozantinib/Atezolizumab vs cabozantinib
❌No improvement mPFS (co-1° endpoint): 10.6 vs 10.8 mos
❌No diff OS (co-1° endpoint): HR 0.94 (95% CI: 0.70-1.27)
❌No diff ORR: 41% both arms
📈Med DOR: 12.7 vs 14.8 mos
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @nataliagandur @MosheOrnsteinMD 5/18 #TumorBoardTuesday #RCC @APoprach @crisbergerot
👨🏻🏫Mini tweetorial 3👩🏻🏫
✨CONTACT-03
📌Cabozantinib/Atezolizumab vs cabozantinib
☢️Tox increased with combo
🔹G3/4: 68% vs 62%
🔹SAE trAE: 24% vs 12%
🔹Drug stopped for AE: 16% vs 4%
🔹Death AE: 6% vs 4%
🔹Death trAE: 1% vs 0%
👨🏻🏫Mini tweetorial 3👩🏻🏫
✨CONTACT-03
📌Cabozantinib/Atezolizumab vs cabozantinib
☢️Tox increased with combo
🔹G3/4: 68% vs 62%
🔹SAE trAE: 24% vs 12%
🔹Drug stopped for AE: 16% vs 4%
🔹Death AE: 6% vs 4%
🔹Death trAE: 1% vs 0%
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @nataliagandur 6/18 #TumorBoardTuesday #RCC
👨🏻🏫Mini tweetorial 4 👩🏻🏫
✨CONTACT-03 ✨
📌Cabozantinib/Atezolizumab vs cabozantinib
❌Results do NOT ❌ support use of anti-PD-L1+TKI after PD on prior IO-based Tx
☢️Toxicity ⬆️ with combo
📚@montypal @tompowles1 @DrChoueiri thelancet.com
👨🏻🏫Mini tweetorial 4 👩🏻🏫
✨CONTACT-03 ✨
📌Cabozantinib/Atezolizumab vs cabozantinib
❌Results do NOT ❌ support use of anti-PD-L1+TKI after PD on prior IO-based Tx
☢️Toxicity ⬆️ with combo
📚@montypal @tompowles1 @DrChoueiri thelancet.com
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd 7/18 #TumorBoardTuesday
👨🏻🏫Mini tweetorial 5 👩🏻🏫
✨TiNivo-2 ✨
🔮Is anti-PD-L1 Ab not as active in #mRCC?
📍anti-PD-1 Ab (nivolumab) + TKI (tivozanib) vs TKI (tivo)
❓Role of IO rechallenge in mRCC
📚@DrChoueiri @HHammersMD @katy_beckermann @DrDanielHeng
ascopubs.org
👨🏻🏫Mini tweetorial 5 👩🏻🏫
✨TiNivo-2 ✨
🔮Is anti-PD-L1 Ab not as active in #mRCC?
📍anti-PD-1 Ab (nivolumab) + TKI (tivozanib) vs TKI (tivo)
❓Role of IO rechallenge in mRCC
📚@DrChoueiri @HHammersMD @katy_beckermann @DrDanielHeng
ascopubs.org
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri @HHammersMD @katy_beckermann @DrDanielHeng 8/18 #TumorBoardTuesday #RCC #RenalCell
👨🏻🏫Mini tweetorial 6 👩🏻🏫
📌TKI monotherapy after prior IO
📍Cabozantinib
✨CANTANA✨
📚 jamanetwork.com
✨BREAKPOINT✨
📚 pubmed.ncbi.nlm.nih.gov
✨CaboPoint✨
📚 ascopubs.org
✨CONTACT-03✨
📚 thelancet.com
👨🏻🏫Mini tweetorial 6 👩🏻🏫
📌TKI monotherapy after prior IO
📍Cabozantinib
✨CANTANA✨
📚 jamanetwork.com
✨BREAKPOINT✨
📚 pubmed.ncbi.nlm.nih.gov
✨CaboPoint✨
📚 ascopubs.org
✨CONTACT-03✨
📚 thelancet.com
thelancet.com/journals/lance…
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
The addition of atezolizumab to cabozantinib did not improve clinical outcomes and led to increased...
ascopubs.org/doi/abs/10.120…
CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
606 Background: First line CPI-based therapy is the standard of care for advanced RCC. There is a la...
pubmed.ncbi.nlm.nih.gov/36447337/
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03) - PubMed
NCT03463681 - A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma...
jamanetwork.com/journals/jamao…
Telaglenastat Plus Cabozantinib in Renal Cell Carcinoma
This randomized clinical trial compares the efficacy and safety of telaglenastat plus cabozantinib v...
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri @HHammersMD @katy_beckermann 9/18 #TumorBoardTuesday
👨🏻🏫Mini tweetorial 7👩🏻🏫
📌TKI monotherapy after IO
📍Tivozanib
✨Tivo-3: tivo v sorafenib (after 2L/3L; ≈26% prior IO/TKI)
📈mPFS: 5.6 v 3.9 mos
🔹ORR 18% v 8%
🔹IO/TKI tx’ed subgroup: PFS HR 0.55 (95% CI: 0.32-0.94)
📚@brian_rini thelancet.com
👨🏻🏫Mini tweetorial 7👩🏻🏫
📌TKI monotherapy after IO
📍Tivozanib
✨Tivo-3: tivo v sorafenib (after 2L/3L; ≈26% prior IO/TKI)
📈mPFS: 5.6 v 3.9 mos
🔹ORR 18% v 8%
🔹IO/TKI tx’ed subgroup: PFS HR 0.55 (95% CI: 0.32-0.94)
📚@brian_rini thelancet.com
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri @HHammersMD 10/18 #TumorBoardTuesday #RCC #KidneyCancer
👨🏻🏫Mini tweetorial 8 👩🏻🏫
📌TKI monotherapy after prior IO
📍Axitinib
✨NCT02579811: 2L axi post-IO Tx ✨
🔹N=40: 63% 1L nivo mono, 15% 1L ipi/nivo
📉ORR 45%
📈mPFS 8.8 mos
📚@kimrynRathmell @GUONCGarciaJA thelancet.com
👨🏻🏫Mini tweetorial 8 👩🏻🏫
📌TKI monotherapy after prior IO
📍Axitinib
✨NCT02579811: 2L axi post-IO Tx ✨
🔹N=40: 63% 1L nivo mono, 15% 1L ipi/nivo
📉ORR 45%
📈mPFS 8.8 mos
📚@kimrynRathmell @GUONCGarciaJA thelancet.com
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri @HHammersMD @KimrynRathmell @GUONCGarciaJA 11/18 #TumorBoardTuesday
👨🏻🏫Mini tweetorial 9 👩🏻🏫
📌TKI/mTOR combo after prior VEGF-targeted Tx
📌Lenvatinib/everolimus
✨RPh II: Len (18 mg/d) + evel (5 mg/d) vs eve (10mg/d) in post-TKI
🔹3% prior IO
🔹Len/eve vs eve: mPFS 14.6 vs 5.5 mos; mOS 25.5 vs 15.4 mos; ORR 43% vs 6%
👨🏻🏫Mini tweetorial 9 👩🏻🏫
📌TKI/mTOR combo after prior VEGF-targeted Tx
📌Lenvatinib/everolimus
✨RPh II: Len (18 mg/d) + evel (5 mg/d) vs eve (10mg/d) in post-TKI
🔹3% prior IO
🔹Len/eve vs eve: mPFS 14.6 vs 5.5 mos; mOS 25.5 vs 15.4 mos; ORR 43% vs 6%
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri @HHammersMD @KimrynRathmell @GUONCGarciaJA 12/18 #TumorBoardTuesday #RCC
Back to our case 🔎
💊Start axitinib 5mg BID
📆6 mos
☢️Tx complicated by HTN
Axitinib dose ⬇️ to 4mg/3mg alternating
🩻PR after 6 mos
PD in multi 🦴 after 18 mos
🧐What treatment do you consider next after progression on ipi/nivo then axitinib?
Back to our case 🔎
💊Start axitinib 5mg BID
📆6 mos
☢️Tx complicated by HTN
Axitinib dose ⬇️ to 4mg/3mg alternating
🩻PR after 6 mos
PD in multi 🦴 after 18 mos
🧐What treatment do you consider next after progression on ipi/nivo then axitinib?
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri 13/18 #TumorBoardTuesday #RCC #KidneyCancer
✨RadiCaL A031801
📌RPh II: Radium-223 + cabo in pts with 🦴mets
☢️Radium-223: alpha emitter ➡️ proven efficacy in mCRPC with 🦴-only mets)
‼️Enrollment ongoing‼️
📚@DrRanaMcKay @DrChoueiri @ALLIANCE_org clinicaltrials.gov
✨RadiCaL A031801
📌RPh II: Radium-223 + cabo in pts with 🦴mets
☢️Radium-223: alpha emitter ➡️ proven efficacy in mCRPC with 🦴-only mets)
‼️Enrollment ongoing‼️
📚@DrRanaMcKay @DrChoueiri @ALLIANCE_org clinicaltrials.gov
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri @DrRanaMcKay @ALLIANCE_org 14/18 #TumorBoardTuesday
Back to our case🔎
65yo 👨🏼 met #RCC to 🫁 & 🦴
💉 1L ipi/nivo x7 months
💊 2L axitinib x18 months
Starts 💊 3L cabozantinib 60mg/d
🩻 Stable disease on cabo
☢️ Requires dose ⬇️ to 40mg/d due to ⬆️ LFTs
🗓️ 8 months
🩻 Scans: new 🫁 nodules
Back to our case🔎
65yo 👨🏼 met #RCC to 🫁 & 🦴
💉 1L ipi/nivo x7 months
💊 2L axitinib x18 months
Starts 💊 3L cabozantinib 60mg/d
🩻 Stable disease on cabo
☢️ Requires dose ⬇️ to 40mg/d due to ⬆️ LFTs
🗓️ 8 months
🩻 Scans: new 🫁 nodules
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri @DrRanaMcKay @ALLIANCE_org 15/18 #TumorBoardTuesday #RCC #KidneyCancer
👆🏽With the above 👨🏼 patient information
🧐 How would YOU treat after PD on ipilimumab/nivolumab, axitinib, then cabozantinib?
👆🏽With the above 👨🏼 patient information
🧐 How would YOU treat after PD on ipilimumab/nivolumab, axitinib, then cabozantinib?
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri @DrRanaMcKay @ALLIANCE_org 16/18 #TumorBoardTuesday #KidneyCancer #RenalCellCarcinoma
🧬 Hereditary #RCC with VHL mutation (VHL Syndrome)
🔹 VHL alterations in 90% of sporadic ccRCC via upregulation of HIF
💊 Belzutifan blocks HIF: 49% ORR; time to treat response ➡️ 8 months
🧬 Hereditary #RCC with VHL mutation (VHL Syndrome)
🔹 VHL alterations in 90% of sporadic ccRCC via upregulation of HIF
💊 Belzutifan blocks HIF: 49% ORR; time to treat response ➡️ 8 months
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @DrChoueiri @DrRanaMcKay @ALLIANCE_org 17/18 #TumorBoardTuesday #RCC #KidneyCancer
Back to our case 🔎
👨🏼 Started tivozanib 1.34mg/d
🩻 Stable disease after 3 mos
👩🏻⚕️ Continue to see patient 👨🏼q6wk
Back to our case 🔎
👨🏼 Started tivozanib 1.34mg/d
🩻 Stable disease after 3 mos
👩🏻⚕️ Continue to see patient 👨🏼q6wk
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd 18/18 #TumorBoardTuesday #RCC
🔥🔥Coming to #ESMO23🔥🔥
@myESMO esmo.org
🔜LITESPARK-005 (LBA88):
Belzutifan vs everolimus post-IO & TKI @ALBIGESL
🔜LITESPARK-003 (LBA87): Belzu/cabo combo @DrChoueiri
🔜LITESPARK-013 (1881O): Belzu safety+efficacy x2 @neerajaiims
🔥🔥Coming to #ESMO23🔥🔥
@myESMO esmo.org
🔜LITESPARK-005 (LBA88):
Belzutifan vs everolimus post-IO & TKI @ALBIGESL
🔜LITESPARK-003 (LBA87): Belzu/cabo combo @DrChoueiri
🔜LITESPARK-013 (1881O): Belzu safety+efficacy x2 @neerajaiims
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @myESMO @AlbigesL #TumorBoardTuesday #GU
🔥🔥SURPRISE LAST-MINUTE BONUS🔥🔥
🔥🔥Perfect timing🔥🔥
With release of @myesmo LBA data today,
@DrChoueiri eloquently breaks down what to watch for at #ESMO23 👇
🔥🔥SURPRISE LAST-MINUTE BONUS🔥🔥
🔥🔥Perfect timing🔥🔥
With release of @myesmo LBA data today,
@DrChoueiri eloquently breaks down what to watch for at #ESMO23 👇
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @myESMO @AlbigesL #PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com
👉🏽ALL CME🔗 integrityce.com
🤔@AmandaNizamMD @YuWeiChenMD taught us progressive #RCC, test yourself
🧐What 3L?
65yo 👨🏽🦳
met clear cell RCC
Progression on 2L axitinib after 1L nivolumab/ipilimumab
👉🏽#CME Eval 🔗 integrityce.com
👉🏽ALL CME🔗 integrityce.com
🤔@AmandaNizamMD @YuWeiChenMD taught us progressive #RCC, test yourself
🧐What 3L?
65yo 👨🏽🦳
met clear cell RCC
Progression on 2L axitinib after 1L nivolumab/ipilimumab
integrityce.com/TBT2023
Tumor Board Tuesday 2023 Conversations
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert fac...
integrityce.com/TBTeval23
Tumor Board Tuesday Evaluation 2023 (ID: i854/i855/i862/i865)
Take this survey powered by surveymonkey.com. Create your own surveys for free.
@TumorBoardTues @AmandaNizamMD @MPishvaian @JohnEbbenMDPhD @ReginaBarCar @Uromigos @DanLinMD @ADESAIONCMD @apolo_andrea @FabioSchutz78 @ERPlimackMD @BourlonMaite @MRoumiguie @diogodrigues @OAlhalabiMD @WalterStadler5 @caPeTTenaTi @TDorffOnc @NBDavisMD @BrunoBastosMD @OncHahn @UrogerliMD @lalaniMD @SoaresAndrey @g_develasco @Ro_Mariano85 @GPloussard @crisuarez08 @shilpaonc @Dominick_Bosse @sutadon_tabetai @urotoday @RamnaraignMD @AlisonBirtle @jose_bdc @MTCOSB @EbrahimiHedyeh @DrYukselUrun @EnriqueGallar12 @Chrislabaki1 @ReneeSaliby @mjmoussa_ @UroDocAsh @SpiessPhilippe @sogug1 @arafflemd @myESMO @AlbigesL #PostTest Q2️⃣ #TumorBoardTuesday #RCC #KidneyCancer
👉🏽 Free CME 🔗 integrityce.com
🧐 What beginning cabozantinib mono dose?
Patient with mccRCC
Disease progression on maintenance nivolumab after 1L nivolumab/ipilimumab
👉🏽 Free CME 🔗 integrityce.com
🧐 What beginning cabozantinib mono dose?
Patient with mccRCC
Disease progression on maintenance nivolumab after 1L nivolumab/ipilimumab
جاري تحميل الاقتراحات...